Articles from Clarametyx Biosciences, Inc.

Clarametyx Biosciences, Inc. (“Clarametyx”), a clinical-stage biotechnology company developing immune-enabling therapies and vaccines to address biofilm-driven chronic respiratory diseases, today announced positive topline data from a Phase 1b/2a clinical trial evaluating its novel immune-enabling antibody therapy, CMTX-101, in the treatment of people with cystic fibrosis (pwCF). These findings support further development of CMTX-101 in a Phase 2 bronchiectasis trial.

Clarametyx Biosciences, Inc. (“Clarametyx”), a clinical-stage biotechnology company developing immune-enabling therapies and vaccines to address biofilm-driven chronic respiratory disease, today announced the promotion of Steve St. Onge, PharmD, MBA to Chief Business Officer, and the hiring of Brendan Doran, PharmD, as Senior Vice President of Clinical Development. These leadership additions position the company to accelerate progress as its pipeline rapidly advances toward later stage clinical development.

Clarametyx Biosciences, Inc. (“Clarametyx”), a clinical-stage biotechnology company developing immune-enabling therapies and vaccines to address biofilm-driven chronic respiratory disease, announced today that it has completed enrollment in its Phase 1b/2a clinical trial evaluating CMTX-101, a novel immune-enabling antibody therapy in development to treat cystic fibrosis (CF)-associated pulmonary biofilm infections. Clarametyx expects to report topline data from the study during the first quarter of 2026.

Clarametyx Biosciences, Inc. (“Clarametyx”), a clinical-stage biotechnology company developing immune-enabling therapies and vaccines to address biofilm-driven chronic respiratory diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track and Qualified Infectious Disease Product (QIDP) Designations under the Gaining Antibiotic Incentives Now (GAIN) Act for CMTX-101’s use to treat people with cystic fibrosis who are affected by chronic bacterial pulmonary infections. Following the recently announced positive interim analysis results in cystic fibrosis, the Company has closed an upsized second tranche of funding associated with its Series A financing from existing investors to support ongoing pipeline activities for both therapeutic and vaccine programs.

Clarametyx Biosciences, Inc. (“Clarametyx”), a clinical-stage biotechnology company developing immune-enabling therapies and vaccines to address biofilm-driven chronic respiratory diseases, announced today that it is advancing a Phase 1b/2a clinical trial evaluating its novel immune-enabling antibody therapy CMTX-101 to treat cystic fibrosis (CF)-associated pulmonary infections, based on the DMC’s approval to proceed following results of a pre-specified interim analysis.

Clarametyx Biosciences, Inc. (“Clarametyx”), a biotechnology company developing targeted, immune-enabling biologic therapies to counter serious infections associated with biofilms, today announced that it has completed the initial Phase 1b portion of its clinical trial evaluating the novel immune-enabling antibody therapy CMTX-101 to treat cystic fibrosis (CF)-associated pulmonary infections and is now initiating the Phase 2a portion of the trial.